Dunnett’s T3 test post-hoc statistical analysis after an ANOVA indicated significantly lower tumor burden in GGPPS inhibitor CML-07–119 treated mice compared to PBS controls (p = 0.020), as well as in cytarabine-treated mice compared to PBS (p = 0.013) (Fig. 5f). Here, GGPS1 is linked to neoplasm.